Diarrhea - Pipeline Insight, 2025

DelveInsight’s, “Diarrhea - Pipeline Insight, 2025” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Diarrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Diarrhea: Understanding

Diarrhea: Overview

Diarrhea is having three or more loose or liquid stools (poos) in one day, or more frequently than normal. Diarrhea episodes are often caused by a stomach bug (gastroenteritis) and clear up on their own in a few days. However, there are many other causes of diarrhea. Most diarrhea is mild, but it can also be severe even needing admission to hospital. Diarrhea is the augmentation of water content in stools because of an imbalance in the normal functioning of physiologic processes of the small and large intestine responsible for the absorption of various ions, other substrates, and consequently water. Acute diarrhea is described as the acute onset of three or more loose or watery stools a day lasting for 14 days or less. However, chronic or persistent diarrhea is labeled when an episode lasts beyond 14 days. Infection commonly causes acute diarrhea. Noninfectious etiologies become more common as the duration of diarrhea becomes chronic. This distinction is important because treatment and management are based on the duration and specific etiology. Rehydration therapy is an important aspect of the management of any patient with diarrhea. Prevention of infectious diarrhea includes proper handwashing to prevent the spread of infection. The term ""acute gastroenteritis"" is synonymously used with ""acute diarrhea""; however, the former is a misnomer. The term gastroenteritis signifies both gastric and small intestinal involvement, whereas, practically gastric involvement is almost never seen in acute diarrhea even if it is the infective form of diarrhea. In developed regions, acute diarrhea is almost always a benign, self-resolving condition that subsides in a few days. The duration of illness and clinical presentation vary on the basis of the etiology of diarrhea and the host factors. For instance, rotavirus commonly presents with vomiting, dehydration, and more workdays lost than nonrotavirus diarrhea.

Typically, a patient with acute diarrhea will have a self-limited course and will not require labs or imaging. A stool culture is warranted in a patient with bloody diarrhea or severe illness to rule out bacterial causes. Bloody stools require additional testing for Shiga toxin and lactoferrin. A patient with recent antibiotic use or hospitalization will require testing for Clostridium difficile infection. Imaging is not ordered routinely in a patient with acute diarrhea. However, an abdominal CT may be required when a patient presents with significant peritoneal signs. In diarrhea, a stool pH of under 5.5 or the abundance of reducing substances signifies carbohydrate intolerance usually secondary to viral illnesses.

An important aspect of diarrhea management is replenishing fluid and electrolyte loss. Patients should be encouraged to drink diluted fruit juice. In more severe cases of diarrhea, IV fluid rehydration may become necessary. Eating foods that are lower in fiber may aid in making stool firmer. A bland 'BRAT' diet including bananas, toast, oatmeal, white rice, applesauce and soup/broth is well tolerated and may improve symptoms. Anti-diarrheal therapy with anti-secretory or anti-motility agents may be started to reduce the frequency of stools. However, they should be avoided in adults with bloody diarrhea or high fever because they can worsen severe intestinal infections. Water is a good way to replace fluids, but it doesn't contain the salts and electrolytes minerals such as sodium and potassium that are essential for our body to function. Empiric antibiotic therapy with an oral fluoroquinolone can be considered in patients with more severe symptoms. Probiotic supplementation has been shown to reduce the severity and duration of symptoms and should be encouraged in patients with acute diarrhea.

""Diarrhea - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diarrhea pipeline landscape is provided which includes the disease overview and Diarrhea treatment guidelines. The assessment part of the report embraces, in depth Diarrhea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diarrhea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Diarrhea R&D. The therapies under development are focused on novel approaches to treat/improve Diarrhea

Diarrhea Emerging Drugs Chapters

This segment of the Diarrhea report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Diarrhea Emerging Drugs

• VE303: Vedanta Biosciences, Inc.

VE303 is an orally administered, rationally-designed, defined bacterial consortium candidate being developed for high-risk Clostridioides difficile (CDI) infection. VE303 consists of 8 types of clonal human commensal bacteria strains selected for their ability to provide colonization resistance to C. difficile and manufactured under CGMP conditions. Currently, the drug is in clinical trial Phase III stage for the treatment diarrhea disease.

• RHB-102: RedHill Biopharma Limited

RHB-102 is a proprietary, bimodal release, once-daily oral pill formulation of the antiemetic drug ondansetron, targeting several gastrointestinal indications. RHB-102 24 mg is intended to provide patients with relief from nausea and vomiting symptoms for a full 24-hour period with a single oral tablet. Currently, the drug is in clinical trial Phase II stage for the treatment diarrhea disease.

• VR-AD-1005: Hunazine Biotech

VR-AD-1005, a novel antidiarrheal investigational drug for the innovative treatment of severe diarrhea of cholera. VR-AD-1005 is intended to work by reducing the volume of liquid stool produced by the intestine when suffering from the diarrheal pathogen. The drug works within the intestine without affecting its motility and does not induce constipation. Currently, the drug is in Phase II stage of its clinical trial for the treatment of severe diarrhea of cholera.

• ShigETEC: Eveliqure Biotechnologies GmbH

ShigETEC is an orally administered vaccine that induces broad protection against Shigella in a serotype-independent fashion and additionally against ETEC, two major pathogens responsible for diarrhoeal diseases. Based on preclinical data generated by Eveliqure over the last 5 years, it has the potential to be a best-in-class diarrhoea vaccine that targets both travelers and populations in low- and middle-income countries. Currently, the drug is in clinical trial Phase I stage for the treatment of diarrhea disease.

Further product details are provided in the report……..

Diarrhea Therapeutic Assessment

This segment of the report provides insights about the different Diarrhea drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Diarrhea

There are approx. 25+ key companies which are developing the therapies for Diarrhea. The companies which have their Diarrhea drug candidates in the most advanced stage, i.e. Phase III include, Vedanta Biosciences, Inc.

• Phases

DelveInsight’s report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Diarrhea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diarrhea Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Diarrhea therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diarrhea drugs.

Diarrhea Report Insights

• Diarrhea Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Diarrhea Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Diarrhea drugs?
• How many Diarrhea drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diarrhea?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diarrhea therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Diarrhea and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• RedHill Biopharma Limited
• Puma Biotechnology, Inc.
• Hunazine Biotech
• Vedanta Biosciences, Inc.
• Crinetics Pharmaceuticals Inc.
• MGB Biopharma Limited
• Daewoong pharmaceutical Co. LTD.
• Eveliqure Biotechnologies GmbH
• Inmunova S.A.
• GlaxoSmithKline

Key Products

• RHB-102
• Neratinib
• VR-AD-1005
• VE303
• Paltusotine
• MGB-BP-3
• DWJ1230
• ShigETEC
• INM004
• altSonflex